<div id="readability-page-1"><p>TRex Bio, Inc. announced that it has received $50 million in a round of funding on January 27, 2026.The transaction included participation from new investors Janus Henderson Investors US LLC, Balyasny Asset Management L.P., Affinity Asset Advisors, LLC, returning investors Alexandria Venture Investments, LLC, Delos Advisors Limited, Eli Lilly and Company (NYSE:LLY), Johnson &amp; Johnson Innovation - JJDC, Inc., Pfizer Venture Investments LLC, Polaris Venture Partners, Inc., SV Health Investors, LLC, Avego BioScience Capital. The company issued convertible preferred shares in the transaction.</p></div>

<p>TRex Bio, Inc. 宣佈於 2026 年 1 月 27 日獲得 5000 萬美元的融資。本輪融資吸引了新老投資者的參與，包括 Janus Henderson Investors、Balyasny Asset Management 和禮來。公司在交易中發行了可轉換優先股</p>

TRex Bio, Inc. announced that it has received $50 million in funding from a group of investors

marketscreener

2 倍做多 LLY ETF - Defiance

基因改革 ETF - ARK

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

禮來

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - Vanguard

Invesco Nasdaq Biotechnology ETF

PROMETHEUS BIOSCIENCES INC

美國制藥 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

醫療業 ETF - SPDR

TRex Bio, Inc. 宣佈已從一組投資者處獲得 5000 萬美元的融資